Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, et al.
Nature (2021) Vol. 595, Iss. 7867, pp. 432-437
Closed Access | Times Cited: 447

Showing 1-25 of 447 citing articles:

Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 423
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Javier Pascual, Gerhardt Attard, François‐Clément Bidard, et al.
Annals of Oncology (2022) Vol. 33, Iss. 8, pp. 750-768
Open Access | Times Cited: 381
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
J. Alfred Witjes, Harman Max Bruins, Albert Carrión, et al.
European Urology (2023) Vol. 85, Iss. 1, pp. 17-31
Open Access | Times Cited: 307
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 282
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Daisuke Kotani, Eiji Oki, Yoshiaki Nakamura, et al.
Nature Medicine (2023) Vol. 29, Iss. 1, pp. 127-134
Open Access | Times Cited: 272
Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution
Dian Yang, Matthew G. Jones, Santiago Naranjo, et al.
Cell (2022) Vol. 185, Iss. 11, pp. 1905-1923.e25
Open Access | Times Cited: 214
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
Davina Gale, Katrin Heider, Andrea Ruiz-Valdepeñas, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 500-510
Open Access | Times Cited: 200
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Everett J. Moding, Barzin Y. Nabet, Ash A. Alizadeh, et al.
Cancer Discovery (2021) Vol. 11, Iss. 12, pp. 2968-2986
Open Access | Times Cited: 193
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Christopher Abbosh, Alexander M. Frankell, Thomas Harrison, et al.
Nature (2023) Vol. 616, Iss. 7957, pp. 553-562
Open Access | Times Cited: 182
Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)
Liang Xia, Jiandong Mei, Ran Kang, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 15, pp. 3308-3317
Open Access | Times Cited: 176
Cancer evolution: Darwin and beyond
Roberto Vendramin, Kevin Litchfield, Charles Swanton
The EMBO Journal (2021) Vol. 40, Iss. 18
Open Access | Times Cited: 175
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
Sumanta K. Pal, Robert G. Uzzo, José A. Karam, et al.
The Lancet (2022) Vol. 400, Iss. 10358, pp. 1103-1116
Open Access | Times Cited: 168
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Debyani Chakravarty, Amber M. Johnson, Jeffrey Sklar, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 11, pp. 1231-1258
Open Access | Times Cited: 167
Bladder cancer
Lars Dyrskjøt, Donna E. Hansel, Jason A. Efstathiou, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 163
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
Jia‐Tao Zhang, Si‐Yang Liu, Wei Gao, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1690-1701
Open Access | Times Cited: 147
Embracing cancer complexity: Hallmarks of systemic disease
Charles Swanton, Elsa Bernard, Chris Abbosh, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1589-1616
Open Access | Times Cited: 140
Circulating Tumor DNA Minimal Residual Disease Detection of Non–Small-Cell Lung Cancer Treated With Curative Intent
Bruna Pellini, Aadel A. Chaudhuri
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 567-575
Open Access | Times Cited: 134
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
Mark M. Awad, Ramaswamy Govindan, Kristen N. Balogh, et al.
Cancer Cell (2022) Vol. 40, Iss. 9, pp. 1010-1026.e11
Open Access | Times Cited: 129
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Pavel Stejskal, Hani Goodarzi, Josef Srovnal, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 125
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Bernadett Szabados, Mark Kockx, Zoe J. Assaf, et al.
European Urology (2022) Vol. 82, Iss. 2, pp. 212-222
Open Access | Times Cited: 116
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
Yan Peng, Wuxuan Mei, Kaidong Ma, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 106
Current and Future Clinical Applications of ctDNA in Immuno-Oncology
Julia-Christina Stadler, Yassine Belloum, Benjamin Deitert, et al.
Cancer Research (2021) Vol. 82, Iss. 3, pp. 349-358
Open Access | Times Cited: 104
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
Nicholas C. Turner, Claire Swift, Ben Jenkins, et al.
Annals of Oncology (2022) Vol. 34, Iss. 2, pp. 200-211
Open Access | Times Cited: 103
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
Mark Jesus M. Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Cancer Cell (2023) Vol. 41, Iss. 6, pp. 1091-1102.e4
Open Access | Times Cited: 82
A clinician’s handbook for using ctDNA throughout the patient journey
Samantha O. Hasenleithner, Michael R. Speicher
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 81
Page 1 - Next Page

Scroll to top